Who is sponsoring NCT01396382?

NCT01396382 is sponsored by Vanderbilt-Ingram Cancer Center.

What drugs are being tested in NCT01396382?

Interventions in NCT01396382: 68Ga-DOTATATE PET scan.

What condition does NCT01396382 study?

NCT01396382 studies Neuroendocrine Carcinoma.

Is NCT01396382 still recruiting?

NCT01396382 is currently completed. Last updated 25 February 2016.

Are results published for NCT01396382?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-02-25 · How we verify

NCT01396382: 68Ga

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors

Completed Phase 2 Results posted Last updated 25 February 2016

What this trial tests

Phase 2 trial testing 68Ga-DOTATATE PET scan in Neuroendocrine Carcinoma in 97 participants. Completed in 1 December 2014.

Timeline

1 March 2010

Primary endpoint
1 May 2014

1 December 2014

Quick facts

Lead sponsor	Vanderbilt-Ingram Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	97
Start date	1 March 2010
Primary completion	1 May 2014
Estimated completion	1 December 2014
Sites	1 location across United States

Drugs / interventions tested

68Ga-DOTATATE PET scan

Conditions studied

Neuroendocrine Carcinoma — all drugs for Neuroendocrine Carcinoma →

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

18 and older, any sex, with Neuroendocrine Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Patients That Experienced a Change in Care Plans After 68GA-DOTATATE PET Scan
Time frame: at 1 year
Determine if the 68Ga-DOTATATE PET scan changes patient care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT, U/S).

Sponsor's own description

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine tumors. The investigators will scan people with this cancer and compare it to other conventional imaging methods to see if it improves patient care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA, Liu E, Blume JD, Clanton J, et al · · 2016 · cited 158× · PMID 26769865 · DOI 10.2967/jnumed.115.163865

Verify or expand the search:

Other recruiting trials for Neuroendocrine Carcinoma

Currently open trials in the same condition.

NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting
NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting
NCT06577987 — Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies · Phase 1 · recruiting
NCT06242119 — Clinical Application of the J-PET Scanner Prototype · recruiting
NCT04524208 — A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 · Phase 2 · active not recruiting

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules · NA · active not recruiting
NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
NCT06105801 — EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing · Phase 4 · recruiting
NCT06399640 — Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01396382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center
Last refreshed: 25 February 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01396382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing